US Pharma MarketingThe post Akeso and Summit’s ivonescimab meets OS goals in NSCLC appeared first on Clinical Trials Arena.
Akeso and Summit’s ivonescimab meets OS goals in NSCLC
The drug has already been approved in China but is under review in the US with a PDUFA date of 14 November. The drug has already been approved in China but is under review in the US with a PDUFA date of 14 November. Akeso and Summit are investigating ivonescimab in a number of oncology indications. Credit: Antonio Marca / Shutterstock.com Akeso and Summit Therapeutics’ ivonescimab has shown further benefit in a first-line non-small cell lung cancer (NSCLC) Phase III study, meeting the key secondary overall survival (OS) endpoint. In the randomised, double-blind, multicentre HARMONi-2 trial (NCT05499390), pre-specified interim analysis…
The drug has already been approved in China but is under review in the US with a PDUFA date of 14 November.
Source: Clinical Trials Arena